Cytokinetics, Incorporated (CYTK) Earnings Call Transcript & Summary
August 4, 2022
Earnings Call Speaker Segments
Diane Weiser
executiveGood afternoon, and thank you for being with us on today's call. Robert Blum, our President and Chief Executive Officer, will kick things off with a short review of the quarter and what has happened recently. Fady Malik, EVP of R&D, will share updates on omecamtiv mecarbil and aficamten. Andrew Callos, EVP and Chief Commercial Officer, will talk about commercialization planning efforts for omecamtiv mecarbil as well as our specialty cardiology franchise strategy for aficamten. Stuart Kupfer, SVP and Chief Medical Officer, will give an update on reldesemtiv. Robert Wong, VP and Chief Accounting Officer, will walk through the financials for the quarter just ended. Ching Jaw, SVP and Chief Financial Officer, will cover our financial outlook and the revised 2022 guidance. Then Robert Blum will wrap up with closing remarks and go over expected upcoming milestones. Please be aware that parts of what we discuss next, including answers to your questions, include statements about future events and performance instead of historical facts, and these are forward-looking statements. Our actual results could differ materially from what these forward-looking statements project. Information about factors that might cause our actual results to differ materially from those in these forward-looking statements can be found in our SEC filings, including our current report on our second quarter 2022 financial results filed today on Form 8-K. We have no obligation to update any forward-looking statements after this call. I'll now hand the call over to Robert.
Robert Blum
executiveThanks, Diane, and I appreciate all of you being with us today. During Q2, we achieved meaningful advances throughout our pipeline, and as we head into the back half of the year, our balance sheet remains solid, including roughly $383 million in net proceeds from our convertible senior notes offering, which closed at the start of Q3. Many of you are aware that obtaining varied sources of capital that don't dilute equity in order to strengthen our balance sheet has been a core principle of our business for a long time, and the money brought in from this deal backs our ongoing advancement and the growth of our pipeline, all aimed at bettering the lives of individuals suffering from cardiovascular and neuromuscular conditions involving impaired muscle function. Notably, over the quarter, we disclosed that a Cardiovascular and Renal Drugs Advisory Committee meeting concerning omecamtiv mecarbil had been set for December 13th, 2022, along with an extension of the PDUFA date for omecamtiv mecarbil to February 28th, 2023. Consequently, we have been able to modify our launch readiness efforts, schedules, and budgets, thereby tightening our spending guidance. We likewise moved forward with our aficamten development program in active trials and by getting ready for extra trials anticipated to kick off later in this year as well as the following year. Regarding reldesemtiv, we kept up enrollment and execution of COURAGE-ALS as planned, and we more recently initiated the open-label extension study, COURAGE-ALS OLE. Beyond these late-stage efforts, our work proceeds on schedule and in line with the targets laid out in our Vision 2025 to advance earlier-stage programs and broaden our pipeline. First, a few words on omecamtiv mecarbil. Taking part in the December advisory committee is our next key milestone. Although we don't have the agenda or particular topics FDA is interested in yet, we anticipate FDA might wish to talk about how broad the possible indication should be, since GALACTIC-HF was run in a wide population exceeding 8,000 patients with heart failure and reduced ejection fraction. The findings showed that the treatment effect of omecamtiv mecarbil appears to be heightened among specific pre-specified and other subgroups of patients whose heart failure is worsening, whether assessed through low left ventricular ejection fraction, elevated NT-proBNP, a recent hospitalization, low blood pressure, or other metrics. FDA could also be interested in addressing the dosing of omecamtiv mecarbil and the way it might be put into practice clinically. In short, our teams are sharply concentrated on getting ready for the advisory committee meeting and will be thoroughly prepared to interact constructively with FDA and its advisors. Simultaneously, we're continuing to move forward on multiple work streams tied to the possible approval and launch of omecamtiv mecarbil. Because of the change in the PDUFA date, we've modified some timelines and the related spending to reflect the potential approval happening in 2023 instead of 2022, which has led us to update our 2022 guidance on spending. Ching Jaw will soon go into more detail regarding how we're extending our cash runway. While our European partnering efforts carry on, we've simultaneously moved forward on a route to approval, and we anticipate filing a marketing authorization application with the European Medicines Agency, or EMA, for omecamtiv mecarbil before this year ends. Should we succeed in securing a partner for omecamtiv mecarbil across Europe, we would anticipate gaining extra capital that supports flexibility in moving our cardiovascular pipeline forward worldwide. Turning to efforts during the second quarter to push aficamten ahead, enrollment and execution of SEQUOIA-HCM keep making progress, and we're delighted by the enthusiasm shown across the many dozens of sites that are set to take part in this study. We likewise kept up planning for a second phase III clinical trial of aficamten in obstructive HCM, and we expect it to begin during the fourth quarter of this year. Later today, Fady will walk through the objectives of that trial in greater depth, explaining its purpose and goals in a way that supports our broader strategy for aficamten. Last, during Q2 we shared the initial longer-term findings from REDWOOD-HCM-OLE, which demonstrated meaningful, sustained drops in LVOT gradients alongside better symptoms and cardiac biomarkers, all accompanied by a favorable safety and tolerability profile. Such findings extend what we saw in the 10-week treatment results from REDWOOD-HCM, and we're eager to share further longer-term findings across 2022 and at 12 months later this year during medical meetings. Moving on to reldesemtiv, we're still enrolling patients and activating centers for COURAGE-ALS, and we just recently launched the COURAGE-ALS open label extension study. We're anticipating the initial interim analysis within COURAGE-ALS, which is intended to test for possible futility. That should take place during the fourth quarter of this year. As our team will tell you today, we're pressing ahead at full speed as we move into the year's second half, backed by a stronger balance sheet that supports our pipeline's advancement, and as we carry out the transformation toward becoming, as we expect, a fully integrated biopharmaceutical company; with that, I'll now hand the call to Fady, please.
Fady I. Malik
executiveThank you, Robert. As we keep talking with the FDA and get ready for the advisory committee meeting we have coming up for omecamtiv mecarbil, it's good to see more analyses coming out that strengthen how we identify the patients who might benefit most from being treated with omecamtiv mecarbil. Those are the higher-risk patients whose heart failure is worsening. This quarter, we shared findings at the Heart Failure 2022 meeting — later published in the European Heart Journal — from a fresh GALACTIC-HF analysis looking at what treatment with omecamtiv mecarbil does in heart failure patients who have reduced ejection fraction along with low blood pressure. What the results demonstrated was a larger treatment effect from omecamtiv mecarbil on the primary composite endpoint of cardiovascular death or first heart failure event than was seen in patients whose blood pressure was not low, and also that blood pressure did not drop further in those patients on omecamtiv mecarbil; compared with placebo, those taking omecamtiv mecarbil showed a lower incidence of treatment-emergent serious AEs and adjudicated first strokes. In this low pressure group, safety for patients on omecamtiv mecarbil was comparable to that of patients on placebo. These findings matter because treating patients with low blood pressure is frequently difficult, and blood pressure frequently becomes a limiting factor when it comes to uptitration and initiation of the standard of care therapies available. The heart failure community did not overlook how important these findings are — many of them told us how valuable this is for their patients, and we had discussions with them after the data presentation. This evidence keeps building, showing that the treatment effect of omecamtiv mecarbil is amplified in patients whose heart failure is worsening, whether that is defined by lower ejection fraction, a recent hospitalization, or, as here, lower blood pressure. As Robert said, we also moved the development program for aficamten forward. This quarter, we presented the first longer-term data from REDWOOD-HCM OLE at Heart Failure 2022, covering 38 patients who completed either 12 or 24 weeks of treatment. According to the data, treatment with aficamten was linked to substantial reductions in the average resting left ventricular outflow tract gradient and the Valsalva gradient. Those reductions began within two weeks of treatment, held through 24 weeks of treatment, and came with only modest decreases in the average left ventricular ejection fraction. Most patients saw an improvement in one or more NYHA class, and there were also significant improvements in NT-proBNP and cardiac troponin, two cardiac biomarkers. Notably, treatment was well-tolerated, with no permanent discontinuations of aficamten. As we anticipate sharing more longer-term data from REDWOOD-HCM OLE later this year, this initial data cut encourages us, supporting aficamten as a next-in-class therapy with a strong safety, efficacy, and tolerability profile. When it comes to creating a treatment that targets what's actually driving HCM, we're equally focused on changing how the disease unfolds — the hallmarks of its progression — and on showing that the harmful thickening and stiffening of the heart muscle caused by excessive contractility might actually be reversed. At the 33rd Annual Scientific Sessions of the American Society of Echocardiography, we shared findings from a REDWOOD-HCM analysis that examined baseline-to-post-treatment shifts in echo-based assessments of cardiac structure and function following 10 weeks on aficamten versus placebo. Our finding: by week 10, patients on aficamten showed better measures of cardiac structure along with diastolic and mitral valve function. Specifically, we saw a meaningful drop in left atrial volume index, a trend toward less left ventricular hypertrophy, better ventricular relaxation and filling, fewer patients experiencing systolic anterior motion of the mitral valve leaflet, and a trend toward fewer cases of eccentric mitral regurgitation. Taken as a whole, this points to aficamten potentially helping with every one of HCM's core defining features — left ventricular hypertrophy, impaired cardiac relaxation, and induced mitral regurgitation — and ultimately enhancing cardiac structure and function. Turning to SEQUOIA-HCM, we're happy to report continued momentum across study startup, enrollment, and conduct, and we now have regulatory clearances in almost all 14 countries taking part, including, more recently, China, where our partner Ji Xing will run the China cohort. Site initiation keeps moving forward in the U.S., and we're bringing many sites online across Europe and China as well. We're working through site startup hurdles tied to the pandemic, which hurt staff availability, and we expect this third quarter to bring additional headway on global site activations and the enrollment that follows. In fact, by the close of Q3, we anticipate most of the planned SEQUOIA-HCM sites will be up and running. With so many international sites and such strong enthusiasm from our investigators, our view remains that enrollment will wrap up in the first half of 2023, and SEQUOIA-HCM results should be in hand during the second half of 2023; separately, across the second quarter we kept enrolling non-obstructive HCM patients into cohort four of REDWOOD-HCM. We've reached close to 50% of the target patient count in this open-label cohort, and its progress has us encouraged. It's possible we'll run an interim analysis of this cohort's data before this year ends, which would help shape planning for potential FDA interactions in the first half of 2023; we're eager to give another update on our next earnings call and to share this cohort's data in the first half of 2023 — data that, if supportive, would allow a potential phase III pivotal trial in non-obstructive HCM patients to begin in 2023. During the second quarter, we also kept up planning work for the second phase III clinical trial of aficamten in obstructive HCM. This further phase III study is meant to give us a clearer picture of how aficamten should be used and where it fits alongside the treatments that are standard right now. Our expectation is that we will kick this trial off during the fourth quarter, and we believe we remain on schedule for that. Let me now walk through some specifics regarding how we intend to structure the study. The design calls for a phase III, multicenter, randomized, double-blind trial that will assess the safety and efficacy of aficamten given as monotherapy versus metoprolol given as monotherapy in patients who have symptomatic obstructive HCM. Metoprolol belongs to the beta blocker class and is frequently prescribed for individuals living with obstructive HCM. Through this comparison against aficamten, our aim is to gauge whether aficamten could potentially be considered a first-line option for patients experiencing symptoms and functional limitations as a result of HCM. We aren't prepared to disclose every aspect of this study at this point, though we did meet with the FDA not long ago and now have alignment regarding the clinical trial design; our hope is that the level of detail we've provided offers some context around what we're aiming to accomplish with this trial and how it might eventually play a role in a potentially differentiated expected label for aficamten; we're eager to reveal further specifics and to get this clinical trial underway for our next in-class drug candidate before this year ends. Switching over to medical affairs at Cytokinetics. As our capabilities have matured over the past quarter, we kept up our hiring efforts and now have our full managed healthcare medical sciences team in place, and we have successfully gotten medical support started for our global value access and distribution activities; another highlight this quarter was holding the first meeting of the Investigator Sponsored Study Review Committee, and we also rolled out a field-based customer relationship management, or CRM, system to assist our medical scientists as they engage with scientific leaders across the country. Looking ahead, we're excited about upcoming presentations at HFSA and AHA featuring additional data from our specialty cardiovascular franchise, and we intend to share the specifics of those soon; with that, I'll hand the call over to Andrew so he can give an update on our commercial readiness efforts in support of our planned specialty cardiology franchise strategy.
Andrew Callos
executiveThank you, Fady. During Q2, our commercial team's efforts centered on bringing people on board for field management along with other work tied to the ongoing launch. Since the PDUFA date has moved into next year, we went back and reviewed and made changes to some of our schedules — especially those tasks that depend on omecamtiv mecarbil possibly being approved and then launched. Specifically, we have pushed back the recruitment of the rest of our first-line sales leaders and customer-facing staff, which includes our sales force of roughly 200 people, so that it happens once the PDUFA date arrives next year. We still intend for two-thirds of the money we plan to spend on the omecamtiv mecarbil launch to be gated so it occurs after that PDUFA date. Every other work stream backing a possible commercial launch is proceeding as expected. In Q2, we finished bringing aboard most of the team based at headquarters, and we now have every essential position for launch filled, covering most of our marketing group, the pricing and market access groups, the analytical and commercial operations groups, and senior sales leadership, plus more than 50% of the first-line sales managers we set out to hire; on the market access side, our groups have been busy talking with major payers to present our clinical, healthcare utilization, and economic information, in line with what FDA guidance says for products that aren't yet approved. When it comes to the supply chain, we carried forward our 2021 momentum, making substantial headway on ERP implementation, serialization, and supply readiness, and also on recruitment, where we've filled important positions in our commercial supply chain. While FDA reviews the NDA for omecamtiv mecarbil, we are likewise holding conversations about possibly using a diagnostic test of plasma concentrations to help guide dose optimization for omecamtiv mecarbil, which would help get the right dose to the right patients and in the end maximize the benefit the drug could deliver. Turning to aficamten, we kept working on our go-to-market strategies across the U.S., aiming to have a preliminary plan ready before the year is out. As we get ready for a possible aficamten launch, we are paying close attention to what's happening in the HCM market and to how Camzyos is launching. What our market intelligence shows is that hundreds of patients are starting treatment, and cardiologists are excited about this new mechanism of action. With the first cardiac myosin inhibitor now available, we are seeing the start of a paradigm shift in how HCM is treated, and we will keep watching how Camzyos launches and is taken up. This lets us grasp the HCM market, pick up insights, and draw lessons from that commercial launch to shape how we plan commercially for aficamten. With that, I'll hand the call to Stuart, who will give an update on reldesemtiv.
Stuart Kupfer
executiveThanks, Andrew. During Q2, we kept adding participants to COURAGE-ALS, and roughly 250 individuals have joined the study so far. Site activation is almost finished across the entire set, with more than 75 locations now up and running worldwide. Investigators continue to show strong enthusiasm for this sizable global phase III study, and we're happy that recruitment is progressing nicely. We're likewise monitoring closely how the landscape for possible ALS therapies is developing. Considerable interest exists in prospective new medications, and given reldesemtiv's muscle-directed mechanism of action along with the encouraging clinical evidence tied to reldesemtiv produced so far, we think it is well-positioned to match what regulatory authorities and patient communities are looking for. Importantly, we're still on schedule for the data monitoring committee to carry out the initial interim analysis of COURAGE-ALS, evaluating futility, during the fourth quarter of this year. That futility assessment was set in motion 12 weeks after roughly one-third of the planned patient count had been randomized. We anticipate the readout of this COURAGE-ALS milestone and hope to then keep conducting the trial. Also, we recently launched COURAGE-ALS OLE, an open-label extension of COURAGE-ALS. Within the OLE, participants will take 300 milligrams of reldesemtiv orally, twice a day, for 48 weeks, and afterward they might move into a managed access program. That managed access program reflects our deep dedication to the patient community and to guaranteeing access to our investigational medicines safely and ethically. Accordingly, any patients who took part in Cytokinetics ALS trials will qualify to join the managed access program, which should begin in the fourth quarter of this year. Even more recently, and only this morning, together with the ALS Association we unveiled a new version of the Pooled Resource Open-Access ALS Clinical Trials Database, or PRO-ACT, which now includes donated clinical trial data from our finished ALS trials, such as BENEFIT-ALS, VITALITY-ALS, and FORTITUDE-ALS. This database holds the biggest ALS clinical trial data set, with close to 11,000 ALS patient records drawn from 23 completed clinical trials. The data have been harmonized and anonymized to form a singular, freely accessible resource for the scientific community; we take pride in adding our clinical trial data to the PRO-ACT database and hope it can help bring about new therapies and possible breakthroughs for those with ALS. With that, I'll hand things over to Robert Wong.
Andrew Callos
executiveAppreciate it, Stuart. We closed out the second quarter with roughly $597 million in cash and investments. For Q2 2022, the bulk of our revenue came from recognizing deferred revenue tied to royalties on net sales of products that contain mavacamten, which happened because royalty obligations were extinguished. R&D expenses for the second quarter of 2022 rose to $57.1 million, up from $36.4 million during the same period in 2021, driven mainly by higher spending on our skeletal muscle program, our cardiac myosin inhibitor program, and our early research programs. As we anticipated, over 50% of R&D expenses stemmed from our cardiovascular programs given the activity around the cardiac myosin inhibitor program, while the rest came from our skeletal and early research activities.
Robert Blum
executiveIn the second quarter of 2022, our G&A costs came to $42.7 million. That's an increase from $21.2 million during Q2 2021, driven by greater spending on commercial readiness as well as higher costs tied to personnel, which takes in stock-based compensation. At this point Ching Jaw is going to go over our financial outlook along with our corporate development strategy.
Ching Jaw
executiveThanks, Robert. We closed out Q2 with a solid financial footing, holding roughly $600 million of cash on the balance sheet. On top of that, during July we brought in about $523 million in net proceeds by offering 3.5% convertible senior notes. Those notes carry a 30% conversion premium and come due in 2027. As part of that deal, we bought back roughly $117 million in aggregate principal amount of our outstanding 2026 notes via privately negotiated transactions. The rest of the money will be allocated across these priorities. To start, we're expanding the aficamten clinical development effort — that means a second phase III trial involving obstructive HCM patients, along with a potential phase III study for those with non-obstructive HCM. Next comes the work of developing commercial infrastructure and conducting readiness efforts within the US, should omecamtiv mecarbil and aficamten receive approval for launch. The third item is advancing our earlier-stage clinical pipeline, which involves transitioning CK-136 into phase II trials and exploring the possibility of creating more cardiac myosin inhibitors aimed at HFpEF. Moving to number four, we intend to extend our research centered on muscle biology to cover energetics, growth, and metabolism of muscle. And finally, the fifth category covers general corporate needs, which includes working capital. We're pleased that we finished a convertible debt offering successfully and made our balance sheet stronger, which helps us move our pipeline forward and grow it. Turning to what we expect for 2022: since the PDUFA date got pushed back, we've revised our guidance and reduced how much net cash we'll use this year. Previously, our projection was operating expenses between $380 million and $400 million, with net cash utilization of roughly $365 million to $385 million. Now we've lowered net cash utilization to about $360 million to $365 million. That change reflects a different timing for hiring our sales force and for spending on activities that are only supposed to happen once omecamtiv mecarbil launches, and that product's PDUFA date is now February 2023. We think our balance sheet, including o. Through the convertible debt offering, the money we brought in gives us enough to cover our cash needs for the next two to three years, and our expectation is that we'll close out 2022 holding over $800 million in cash. With that said, I'll hand things back to Robert Blum.
Robert Blum
executiveThank you, Ching. As we move into the latter portion of 2022, our financial position is solid, numerous programs are moving forward throughout our pipeline, and a commercial transformation is in progress. We are assembling teams and building capabilities, taking part in new activities and work streams, while simultaneously striving to grow our pipeline by pushing earlier-stage drug candidates ahead. As Ching noted, we brought in over $500 million via our convertible debt offering. With these proceeds, we can move CK-136 into early development during this latter half of the year, aiming to define our approach for proof of concept phase II studies that should be underway in 2023 in specialty cardiovascular indications that would complement omecamtiv mecarbil. This program provides a completely new avenue for value, and we look forward to updating you on further developments. In addition, this new capital lets us accelerate new compounds emerging from our research, consistent with the objective set out in our Vision 2025 of having 10 therapeutic area programs running by 2025. You should anticipate hearing more about new INDs in the months ahead. As our company grows, we are continuing our business development discussions, and we intend to build on our long track record of deal-making to further strengthen our balance sheet and, ultimately, deliver our therapies to more patients worldwide. In the second quarter, we moved forward with discussions centered on potential partnerships in Asia and also in Europe, including partnering omecamtiv mecarbil in Europe and partnering both omecamtiv mecarbil and aficamten in Japan. We are being thoughtful in these interactions, since we intend to select the right partner and the right deal structure in each geography, while also safeguarding rights, responsibilities, and economics for Cytokinetics, as we believe this serves the interests of our science as well as our confidence in our ability to execute on what should matter to our shareholders. Lastly, we are now expanding our footprint beyond South San Francisco, and we will open a small East Coast office outside of Philadelphia later this summer. That will be for employees primarily in our commercial, medical affairs, and supply chain teams. This new office marks an important milestone in our growth and maturation into a fully integrated biopharmaceutical company and will hopefully enable us to keep attracting top talent on both coasts; now, I would like to recap our upcoming milestones; for omecamtiv mecarbil, we expect to take part in an advisory committee meeting to review the NDA for omecamtiv mecarbil on December 13, 2022. We also expect to launch omecamtiv mecarbil in the U.S. pending FDA approval in Q1 2023. For aficamten, we expect to keep enrolling patients with obstructive HCM in SEQUOIA-HCM through 2022, with results expected in second half 2023. We also expect to keep enrolling patients with non-obstructive HCM in cohort 4 of REDWOOD-HCM, with data expected in first half 2023. Additionally, we anticipate launching a second phase III study of aficamten for obstructive HCM during Q4 2022. We also plan to provide further longer-term findings from REDWOOD-HCM OLE, the open-label extension trial of aficamten, in second half 2022. Regarding CK-136, our expectation is to restart that development program in second half 2022. As for reldesemtiv, we look for the data monitoring committee of COURAGE-ALS to carry out the initial interim analysis from that trial in this next Q4 2022. On ongoing research, we aim to move forward new muscle-directed compounds and to perform IND-enabling studies for 1 to 2 potential drug candidates. Operator, with that, let's now open the call to questions, please. Good afternoon, Justin.
Justin Kim
analystHey Robert. Afternoon, and I appreciate you fielding these questions — congratulations on everything that's been accomplished. I suppose I'm attempting to link up the various points you've raised. Given that you're guiding toward IND-enabling work on 1 to 2 drug candidates in the coming year, plus what was said earlier in this quarter regarding possible extra myosin inhibitors aimed at HFpEF in particular, I'm curious whether it's reasonable to think HFpEF would be a main indication of focus, and whether those would be new compounds compared with aficamten, going after it.
Robert Blum
executiveExcellent question — I'll begin, then have Fady expand. Please do assume that HFpEF holds major interest for us when it comes to the mechanism of cardiac myosin inhibition; as for which compound or compounds might move forward there, that remains to be settled. Perhaps Fady can say more about our thinking on that.
Fady I. Malik
executiveRight. So I'd say, when it comes to what's happening in that space, the key issue is how you define the patient population, and that's really shaped by what we've been doing in NHCM. Those NHCM patients share a lot of characteristics with the HFpEF population. And I think if you're considering how to move a program forward in HFpEF, you'd want to pay attention to what we're finding out in NHCM, which we might be sharing early next year, and which could signal where we're headed.
Justin Kim
analystAll right, that's helpful. Perhaps one quick additional question before I join the line. I realize this isn't tied specifically to how the phase III trial for the second aficamten study in oHCM was designed, but as far as the company is aware, has any trial of a beta blocker shown prospectively that exercise capacity improves in oHCM patients?
Fady I. Malik
executiveI can take that one. Yes, a good paper came out at the close of last year that essentially examined a crossover trial involving patients receiving metoprolol who were then switched to placebo, and the reverse as well — some began on placebo and were moved to metoprolol. They examined how it affected the gradient, symptoms, and exercise performance measured through peak VO2, and I believe that reference offers a solid baseline for understanding what beta blockers do in HCM; typically they lower the gradient. You do observe a bit of symptomatic benefit. No gain in exercise capacity appears, partly since they restrict how much heart rate can rise, and they also, as you know, come with side effects that certain individuals consider troublesome; that paper from Dibble et al in JACC serves as a good benchmark for beta blocker effects in HCM, at least in the near term. Those were short-term studies.
Justin Kim
analystGreat. Thanks so much.
Robert Blum
executiveThank you.
Robert Blum
executiveHi there, Akash.
Ivy Wang
analystHey, this is Ivy speaking on behalf of Akash. We appreciate you taking our questions. If we could, we have a couple of things to ask. First, regarding mavacamten's label — the advantage seen with mavacamten was fairly modest among patients receiving beta blocker therapy versus those who weren't. Could it be that doctors might have to discontinue beta blockers prior to initiating mavacamten? And additionally, from what you know, what share of oHCM patients receive beta blockers in the real world? Then the second thing is really regarding drug pricing. Since Medicare plays a big role in the cardiovascular area, what effect do you expect this bill to have on your evaluation? And would you think about partnering on any assets? Those are all my questions. Many thanks.
Robert Blum
executiveSure. I believe you raised three questions. Let's address them individually. The first one concerned our understanding of the mavacamten label. Is that correct regarding beta blockers? Could you say that again, please?
Ivy Wang
analystRight, that's it.
Robert Blum
executiveCan you say that question again — what exactly are you asking about?
Ivy Wang
analystOh, absolutely. What I'm getting at is that the advantage seen with mavacamten was fairly modest among patients taking a beta blocker versus those who weren't.
Robert Blum
executiveFady, could you please handle that one?
Fady I. Malik
executiveSo, I suppose when people examine the subgroup analyses from EXPLORER-HCM, the effect seems to be reduced among patients taking beta blockers. There is some wording about that in the FDA materials. I think other analyses have demonstrated that improvements do appear in those patients, even though they are receiving beta blockers. Naturally, to be enrolled in the trial, they still needed to have high gradients and, one would describe them as not fully treated with their beta blockers. I believe that is really a matter of examining the data somewhat more closely. Your other point concerned what proportion of patients take beta blockers, and then approximately 70%-80% of patients begin with beta blockers and remain on them as their initial therapy for oHCM. Specifically, metoprolol tends to be the preferred drug. That, I think, addresses both of your questions.
Robert Blum
executiveQuestion number three, if I understand it right, has to do with laws about Medicare and price negotiations, plus what that could mean for aficamten. Did I get that right?
Ivy Wang
analystYes, that's right.
Robert Blum
executiveTo me, guessing where the floor will be feels premature. Still, I do notice certain carve-outs emerging, possibly tied to orphan indications and specialty indications, where the competitive dynamics may differ and where pricing pressures and budget impact may not be the same. My guess is that this will keep shifting and remain fluid for a while, and going down the road of how it might affect aficamten seems premature, especially since this could eventually turn into legislation. As time goes on, we'll be evaluating that and how it could influence our potential business interests. At present, aficamten sits in phase III, so our attention stays on clinical research.
Ivy Wang
analystGot it. That's really useful, thanks a lot.
Robert Blum
executiveThanks.
Robert Blum
executiveThank you.
Robert Blum
executiveHello, Madhu.
Rob Marcus
analystHi there, it's Rob here, calling in on behalf of Madhu. We appreciate you fielding our question. In 2022, which areas exactly do you plan to cut costs? And regarding the sole AdCom, what's the right way for us to view the possibility of label clarification?
Robert Blum
executiveLet's handle each of those separately, and I'll begin by perhaps turning to Ching and then to Andrew to talk about where we could find some savings when it comes to commercial spending in 2022; after that, maybe Fady and I will address how we might approach the ad com, though I imagine you understand we can't say too much about what's ahead, since we don't even know yet what the questions or the agenda will be. Let's begin with what you asked about funding.
Ching Jaw
executivePerhaps I should begin, and after that I'll pass things along to Andrew. Our intention had been to bring the sales team on board solely once omecamtiv mecarbil secured approval. At first, the PDUFA date fell at the close of November in the current year. Now it has been moved to February in the following year. Take December's field force expense as an illustration — that would shift into next year, and the same goes for certain marketing outlays, media buying expenditure, and agency fees; a portion of those will likewise slide into 2023.
Fady I. Malik
executiveTim, maybe the sole point I'd tack on is that 2022 sees just a slight decrease, since the PDUFA date falls in November. Those efforts are largely sliding into 2023, early 2023, because our expectation was to have the field force ready in January, and at this point that shifts back by several months. Only a slight decrease for 2022, owing to the late PDUFA, the initial PDUFA date at the close of November.
Robert Blum
executiveAlso, as we move into the year's latter half and take stock of the conditions we're facing, we're applying real scrutiny to our updated plans for financial outlays throughout the company; we found additional areas where we believed savings could be achieved during this year, and in our view that simply reflects prudence and sound management. As for your next question about what labeling might be expected, I doubt we can truly address it properly while we still lack more thorough conversations with FDA and before something like an ad com takes place; we ran the GALACTIC Study, and as you're aware, that trial included a heterogeneous population with HFrEF, yet we observed stronger efficacy within a pre-specified subgroup of patients whose ejection fraction was lower, and also within other subgroups — some pre-specified, others post hoc — and together these add to an understanding that efficacy is magnified among patients whose heart failure is worsening. There might be a discussion in which we could consider what the indication ought to be for patients at higher risk. Such matters could be covered via graphs, tables, and figures within a potentially approved package insert, or alternatively in the indication statement. In the end, those are decisions for FDA and its advisors to make and to speak about. I'm unsure whether my answer satisfies you adequately, but I'm certain you appreciate that this may be all we can offer at present.
Rob Marcus
analystYeah, I appreciate that. Thank you for taking our questions.
Robert Blum
executiveThank you.
Robert Blum
executiveHello.
Yasmeen Rahimi
analystHello, Robert, and hello to the rest of the team. I really appreciate you taking the time for my questions. First, thanks for giving us a bit more visibility into the second phase III trial you're planning in obstructive HCM and thinking about conducting it for the possibility of becoming a first-line therapy. How should we approach thinking about the effect size for that trial, and what evidence—sorry if I'm repeating myself—is available with aficamten that gives us confidence we can be just as competitive as first-line therapies, or even better?
Robert Blum
executiveYes. I'll kick things off briefly, then ask Fady to build on those remarks. Given that we think aficamten could be a next-in-class option, it falls to us, as we've said, to move the field forward; we see a substantial opportunity here to show that cardiac myosin inhibition may have potential beyond where the field stands right now. That's why we're interested in running this trial. I'll have Fady go into more detail on the rationale.
Fady I. Malik
executiveAppreciate that, Robert. Look, I'd say it's likely too early on my end to get into particulars around figures and the powering side of things and all of that. What we'd anticipate, though, is a meaningful difference in treatment effect when measured against beta blockers. Keep in mind that aficamten is what we're currently studying, layered on top of standard of care, and also in contrast with patients receiving standard of care. If you like, our view is that aficamten given as monotherapy can deliver an equivalent level of efficacy. Should we be able to pull that off in patients who are, again, essentially on beta blockers as monotherapy, then our expectation would be effects that are comparable to, or perhaps even larger than, what we intend to see in SEQUOIA-HCM. That, I believe, addresses part of what you're asking. Such a result would point toward, you know, a trial smaller in size than SEQUOIA-HCM being sufficient to show those effects.
Yasmeen Rahimi
analystUh-
Fady I. Malik
executiveYou know, I believe there's something else. Oh, please, go on. Were you wanting to?
Yasmeen Rahimi
analystNo, my question was simply about what the gating factors are for getting that study underway. Is the remaining work mainly additional talks with the agency to lock down the protocols, or is there something else? Sorry for cutting you off there, Fady.
Fady I. Malik
executiveThat's quite all right. Launching any trial is a complex undertaking, particularly when you are double blinding against an active comparator. You've got to manufacture the drug and a placebo for the active comparator, and you've got to set up the trial's electronic systems and so forth. Getting a study off the ground takes a great deal of effort. In a sense, if you — the study has already begun, in that we are initiating all of those preparations and putting in substantial work to get it launched. We anticipate engaging with sites before long so we can deliver it to them in time for the end of the year. The final point I wanted to make on this question is that the field, I believe, ultimately wants to know how these therapies compare with each other. The sole means of accomplishing that is running side-by-side trials and examining endpoints that address not just functional and symptom improvement, but also disease modification over time. I believe each of those elements matters for the field to grasp how to use these therapies and sequence them.
Yasmeen Rahimi
analystExcellent. I really appreciate you giving me the chance to ask these.
Fady I. Malik
executiveThanks, Yasmeen.
Robert Blum
executiveHey there, Salim.
Mike Linden
analystHello, this is Mike Linden, filling in for Salim. We really appreciate you answering our question. If I could, I'd like to ask about aficamten and the Camzyos launch that happened recently. As you speak with physicians and those who prescribe, I'm interested in hearing your perspective on the direction the myosin inhibitor market is taking — perhaps what has been gathered up to now, where adoption is occurring, or whether any obstacles exist, anything along those lines. As a follow-up, maybe just whether, based on the data that exists, naturally, you believe this could be a switching market rather than one involving new patients.
Robert Blum
executiveYeah. In this area, we've been carrying out our own efforts while also gaining insight from what equity research analysts and investors have done — every one of them appears quite tuned in to this launch and approaching it in a manner that I'd say is now converging. Things appear to be progressing nicely with the launch. It looks like the launch is unfolding in line with what was expected. It appears there could be hundreds of patients already begun on mavacamten, and free drug is plentiful out there. A portion of it is a 30-day supply, a portion exceeds 30 days, and it usually arrives via specialty channels. The reactions we're picking up on seem favorable. I'll have Andrew address a few of these points in detail, and Fady too, should he want to, about what our commercial and medical teams are specifically teaching us. Regarding your question about patients switching, I assume you're referring to beta blockers, or else are you asking what our strategy would be? If it's the second one — our strategy — then speaking to it now would be too early. Without question, this is a fresh product launch featuring a novel mechanism, and what matters most is that education and awareness keep growing regarding Camzyos and the way it can help patients who, until now, have had little reason for optimism. Mavacamten looks like a genuinely significant new medicine. Perhaps I'll have Andrew and Fady weigh in on whatever else they're picking up regarding the launch.
Fady I. Malik
executiveRight. Robert, the one thing I'd add is that the adoption is mostly happening at HCM centers and with the cardiologists tied to those centers. With BMS, the launch is proceeding the way we anticipated. On the commercial side, payer coverage is beginning. As medical exceptions get worked through, patients are able to obtain the drug, probably via free programs and hub services. Physicians are building familiarity, and as that familiarity grows, they'll keep putting more patients on the product. As far as we can see, from a mechanism standpoint this is a transformation for patients who have HCM and, you know, once again, it's moving along as we expected. Fady, I'm not sure whether there's anything you'd like to add or whether Robert and I have covered it.
Robert Blum
executiveYeah, I think that covers it well.
Mike Linden
analystI really appreciate it.
Robert Blum
executiveClearly, we're still in the early stages of this launch, but everything appears to be progressing nicely. From that perspective, my sense is it shows how much excitement there is around the mechanism.
Mike Linden
analystThanks, guys. Appreciate it.
Robert Blum
executiveThank you.
Joe Pantginis
analystHello, everyone, and good afternoon. I appreciate you taking my question. I have 2 questions regarding omecamtiv mecarbil. The first, I suppose, is more administrative, while the second takes a broader view. On the administrative side, I just want to confirm: is all of the PK data the FDA asked for now available, and have you given it to them, and is there anything further still pending that you must supply?
Fady I. Malik
executiveAt this stage, we have supplied all that they requested, though that does not stop them from requesting additional items later on.
Joe Pantginis
analystNo, naturally. What I want to ask about is bigger picture — regarding how ready you are in the market, and more specifically, the marketing research you may be doing. I suppose my question is this: when it comes to the market being ready to accept this, meaning as you speak with doctors and the wider cardiovascular care community focused on heart failure, how quickly do you believe the drug could be integrated into the treatment paradigm, alongside other drugs, and is the market already embracing the idea that omecamtiv works in a complementary way?
Robert Blum
executiveClearly, promoting omecamtiv mecarbil is not something we can do before it might get approved. There are things we're able to watch that would help enable that, we hope, once approval comes. I'm very happy with the way we're using this additional time in particular to get set for a commercial launch at the point when that happens. Perhaps I could have Fady address how we expect the guidelines to develop, and Andrew, if you have anything more you'd like to say.
Fady I. Malik
executiveSure. So when you look at the studies on omecamtiv mecarbil that have been released, along with the results that have appeared concerning EF, reduced blood pressure, and additional factors. When guideline committees are figuring out where a therapy belongs, our hope is they'd recognize that for individuals who haven't done well on foundational treatment—those who've received the maximum foundational therapy they can handle yet remain unwell with high-risk characteristics like being hospitalized, repeated hospitalizations, elevated NT-proBNP, or similar markers—omecamtiv mecarbil could be viewed as a choice. Looking at today's guidelines, there's essentially that "what comes next" box. Once all other options have been exhausted, what's left to try? So what could be coming down the pipeline? Omecamtiv mecarbil is one we view as a potential follow-on treatment, among others.
Andrew Callos
executiveSure. To add on from the perspective of market research, we attend medical congresses, we speak with KOLs, we run commercial advisory boards, and we carry out what's known as a demand study. In that study, we attach a label — the one we believe represents the target label, based on where we expect it to end up once approved — and place it in front of physicians, then ask them about utilization. From that, you can largely produce your estimate of what market share and demand will look like. Without exception, when we pose these questions to physicians — cardiologists, specifically — the response we get is always comparable: there's a small set of patients, or a specific patient profile or patient type, that they have in mind and know they'd use this product for. We're feeling good about the launch. We're feeling good about the profile in worsening heart failure, and we're feeling good about what physicians tell us regarding utilization for the right patients. Naturally, the real test comes at launch, once we have the final label, but on the whole, demand looks suitable for a launch and for our utilization, given the field force we're planning to deploy.
Joe Pantginis
analystGot it. Thank you very much.
Robert Blum
executiveAnother way.
Joe Pantginis
analystI appreciate that, and Robert, my apologies.
Robert Blum
executiveNo problem — I’ll wrap up with one last thought. If you step back, you can ask which indicators tend to signal whether a commercial launch will go well. People are very familiar with omecamtiv mecarbil. They also recognize how substantial the unmet need is, and that today’s guideline-mandated therapies leave that need unsatisfied. Meanwhile, guidelines keep being revised more often. In our view, those are encouraging signals that, when the moment arrives, the launch could turn out to be a strong one.
Joe Pantginis
analystUnderstood. Thanks again.
Robert Blum
executiveThank you.
Fady I. Malik
executiveThanks, Joe.
Robert Blum
executiveHey, Carter.
Edwin Zhang
analystThanks. Hi, everyone. Edwin here, calling in for Carter. We'd like to pose a follow-up regarding the Camzyos launch question. Now that a therapeutic option exists in this new landscape, could you specifically share any perspective on how diagnosis might be affected, or give us an initial impression of the REMS program's burden, or of monitoring, based on what you've heard from KOLs and stakeholders? For our second question, could you lay out what you anticipate for the possible readout of Cohort 4 from Redwood? Thanks.
Robert Blum
executiveYeah. On the first point, I don't believe we're going to engage in discussing a competitor's launch at any length; we expect mavacamten is performing well, yet regarding how that could ultimately be shaped around the sorts of matters you're raising, I don't think it falls to us to be answering those things for you. What matters more, in my view, is that the equity research community conduct its own independent analyses of such matters. I apologize for that, but I simply sense it may be inappropriate for us to be addressing items at that degree of detail. What was your second question? Or we just
Edwin Zhang
analystYeah. No, no problem.
Robert Blum
executiveW-
Edwin Zhang
analystAll right, so we were just hoping to pose a question.
Robert Blum
executiveRobert Blum, our CEO: Understood. Just a moment.
Edwin Zhang
analystUnderstood. Please proceed, Fady. Thanks.
Fady I. Malik
executiveRegarding whatever they may anticipate from us in terms of reporting for cohort 4 — you know, data from cohort 4 — as we've previously stated, we are examining a lot of the same parameters that were assessed in cohorts 1, 2, and 3, apart from left ventricular outflow tract gradients, since these patients don't have those. Safety and tolerability — we'll be evaluating NYHA class movement. We'll be evaluating biomarkers such as NT-proBNP and troponin; we'll be evaluating echocardiographic response, whether that's declines in LVEF, but additionally we want to take a closer look at changes in cardiac structure and function and diastolic function. You know, all of those items, as you've watched us report for mavacamten in the obstructive HCM cohorts — you know, we intend to likewise perform the same type of measurements and report those for the non-obstructive groups.
Edwin Zhang
analystThank you.
Robert Blum
executiveThank you.
Robert Blum
executiveHey, Jason.
Jason Butler
analystHi there, and thanks for the question. Robert, you said that one of the possible topics for discussion regarding the omecamtiv mecarbil outcome you're getting ready for involves dosing and ideas about how to apply it, you know, in clinical practice. Could you share your thinking on how you intend to guide and teach physicians so they can determine the correct dose and keep the patient at that correct dose? And then you also brought up essentially a companion diagnostic. Once a launch happens, how soon do you believe something like that might be put in place? How would that shift the approach, broadly speaking, for bringing patients onto the therapy? Thank you.
Robert Blum
executiveYes. Maybe I'll start, and maybe I'll also correct one thing you mentioned. As you know, in GALACTIC we employed a method for assessing PK exposures that allowed dose titration for patients up to a target dose level. How we ultimately got patients to target doses as defined by PK parameters has been described and is published. But what I'd like to highlight is that you said companion diagnostic, and strictly speaking, it isn't necessarily a companion diagnostic in the literal meaning of that term. On that front, we're looking at a range of possible approaches. These would support various strategies for getting patients up to the target dose, and they'd allow for the use of different assay types that could prove helpful in clinical practice once we move past what a clinical trial relied on. How we handle that after launch is still fairly fluid. We'll share more as time goes on, as we evaluate the alternatives and choices available. Unfortunately, that's about as much as I can offer at the moment. Fady or Andrew, I don't know if either of you wants to give it a try. We want to reach a point where doctors can achieve the optimal target dose using a PK assay, though the exact method for doing so isn't ready yet—we plan to share that information soon.
Jason Butler
analystAll right, that's great. I appreciate it, and thanks for taking my question.
Robert Blum
executiveHello, Charles.
Charles Duncan
analystHello there, good afternoon, Robert and the rest of the team. Congratulations on the advancement achieved during this quarter, and I appreciate you fielding my question. I had a lengthy question with several parts regarding OMI, plus another question concerning reldesemtiv and that program too. So regarding OMI, the question with multiple parts is this: as you get ready for the outcome, there are roughly 4 months left. Could you give us some detail about, really, the work plan? Are you intending to hold mock adcoms and, if that's the case, what number, or at minimum 1? And what would be the single key focus you consider when it comes to a high-burden patient? Would it be ejection fraction, or would it be hospitalization, or blood pressure? Which one do you believe would be the most compelling?
Robert Blum
executiveYes. I'll have Fady address how we are getting ready, but yes, a mock ad com is something we will hold. We'll carry out a number of these various kinds of preparations so that we are best suited and best prepared, in which the team — and there's a core team — is already working very feverishly right now on these preparations and meeting frequently each week. Fady, anything you want to elaborate on?
Stuart Kupfer
executiveSo look, it goes without saying that our prep work has our full attention right now. There isn't a set agenda or list of subjects in place at this point, you know, but we definitely have plenty on our plate — pulling together background documents, finalizing slide decks, and running mock panels so the team gets reps at handling questions. I'd say our team is excellent, deeply seasoned, and has spent many years on this drug, and by now, you know, they've been through filing an NDA and navigating the approval process. When the moment arrives, we'll be set.
Charles Duncan
analystAll right. I don't question that at all. I'm excited for it. Then, regarding reldesemtiv, maybe this one's for Stuart. It's intriguing that there's hopefully some advancement being made, at least among a portion of them, when it comes to paradigm. In relation to the COURAGE-ALS program you're running, I suppose what I'd like to know is whether you can offer some clarity on what an interim analysis for futility actually entails. I understand the broad idea, but I'm curious whether there's a particular type of result you anticipate from that one-third of patients at 12 weeks. And beyond that, could you also say whether, inside the OLE, any patients have in fact enrolled? I believe you mentioned something along those lines, but I wasn't certain I heard it.
Stuart Kupfer
executiveThanks, Charles. So the interim analysis is pretty uncomplicated. It's a fairly low bar, I'd say, for keeping the trial going. What we're really trying to figure out is whether, you know, there's a trend, a favorable trend, you know, when it comes to the main outcome for reldesemtiv, you know, versus placebo. We absolutely anticipate that, given our phase two data. It's really just a question of being efficient and, you know, responsible when it comes to study conduct and doing what's best for the development program and what's best for patients.
Charles Duncan
analystNow, when it comes to OLE.
Stuart Kupfer
executiveWith the OLE, we're only beginning, so we're right at the point where patients are starting to move over into the open label extensions, and we're quite excited and proud that this is something we can provide to those patients.
Charles Duncan
analystAlright, that's great. I appreciate you letting us ask.
Stuart Kupfer
executiveYou're welcome.
Rohit Basu
analystHi, this is Rohit.
Robert Blum
executiveHello.
Rohit Basu
analystThis is for Serge Belanger. Hello there, and I appreciate you fielding my question. Could you discuss what impact the delays with the FDA on omecamtiv have had on any potential partnership talks? Also, is there anything you can tell us about what providers are saying in response to the ALS database data? Thank you.
Robert Blum
executiveAbsolutely. As far as partnering goes, my view is that the extension of the PDUFA date hasn't made a difference. Talks are ongoing, and I believe prospective partners regard this as perhaps more routine nowadays, particularly with novel mechanisms. The way we're pursuing our partnering strategy remains unchanged. On your other question, would you mind asking it again?
Rohit Basu
analystAbsolutely. Yeah. Could you tell us anything about what providers are saying in response to the information in the ALS database?
Robert Blum
executiveOh, you mean the press release that came out this morning. The response, I'd say, is largely appreciative. This is a discussion we've had for a good while with those who run and oversee the PRO-ACT database. We have now provided a significant addition to that database, covering the data from these 3 completed studies. Bringing our data into PRO-ACT was something that was envisioned, evaluated, and scheduled over a long period. Fady, perhaps you or Stuart would like to add something here? Stuart?
Stuart Kupfer
executiveRight, so this is — you know, I'd say it's simply one more instance of Cytokinetics acting as global citizens, and, you know, we possess these strong datasets coming out of earlier clinical trials; clearly we are extremely dedicated to discovering therapies that can aid these patients. My sense is that, you know, the feedback coming our way is very, very favorable, and this only goes to show even more how devoted we are to this community and to these patients.
Robert Blum
executiveSure, I could also note that because Cytokinetics is known within the ALS community for running sizable, highly disciplined, and strong clinical studies, there seems to be a perception that this is data of great integrity, which ought to create a substantial difference and a substantial effect when it comes to getting them into this database.
Rohit Basu
analystThank you.
Robert Blum
executiveThank you.
Robert Blum
executiveWe appreciate that, operator. I want to thank everyone for being with us on today's conference call. It's evident that we achieved a great deal of meaningful progress during the second quarter. Once again, more recently here in the third quarter, we have laid the groundwork, in our view, for a highly successful second half of this year as well as our entry into next year — something that could prove transformational for Cytokinetics, for its science, for patients, and in the end for shareholders too. We genuinely value your continued support and your enthusiasm for the work we are doing, and we look forward to what's ahead. Operator, with that said, we are ready to bring the call to a close now, please.
Operator
operatorThat wraps up the conference call for today, sir. We appreciate everyone for joining in. You're welcome to leave the line now, and we hope the rest of your day goes well.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Cytokinetics, Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Cytokinetics, Incorporated earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cytokinetics, Incorporated or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.